Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Neurocognitive Disorders

Ketamine for Neurocognitive Disorders

25 papers and 14 clinical trials exploring ketamine as a treatment for neurocognitive disorders.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
IndicationOver 50 million people worldwide suffering from dementia-related disorders.

Neurocognitive Disorders

Neurocognitive disorders, including conditions like dementia and Alzheimer's disease, are characterized by a significant decline in cognitive function. Recent research suggests that psychedelics may offer potential therapeutic benefits by promoting neuronal connectivity and enhancing psychological recovery in these patients.

Full Neurocognitive Disorders profile

Academic Research

25 papers
Open Accessindividual

Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial

In a randomised controlled trial of 51 adolescents with major depressive disorder and suicidal ideation, three subanaesthetic esketamine infusions (0.25 mg/kg) did not impair cognition and were associated with improved processing speed and some improvement in working memory by Day 12. Baseline cognitive performance did not predict antidepressant or antisuicidal response.

Published
September 14, 2023
Journal
Child and Adolescent Psychiatry
Authors
Lan, X-F., Wang, C-Y., Zhang, F., Liu, H., Mai, S., Ning, Y-P., Zhou, Y-L., Hu, Z., Li, W., Ye, Y.
Paywallindividual

Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression

This open-label study (n=66) finds that four ketamine infusions (35mg/70kg) led to improvements in cognition both immediately (measured after the first and fourth infusion) and up to five weeks later. As seen in other studies, antidepressant effects reverted to baseline at five weeks.

Published
April 14, 2023
Journal
Journal of Affective Disorders
Authors
Zavaliangos-Petropulu, A., Mcclintock, S. M., Khalil, J., Joshi, S. H., Taraku, B., Al-Sharif, N. B., Espinoza, R. T., Narr, K. L.
Paywallindividual

Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition

This open-label study (n=25) explored the effects of using intravenous ketamine to treat treatment-resistant depression (TRD) in participants over the age of 60. Depressive symptoms improved significantly, 48% of participants responded, and during the acute phase, executive function measures and the fluid cognition composite score improved (Cohen's d = 0.61).

Published
December 4, 2022
Journal
American Academy of Clinical Psychiatrists
Authors
Oughli, H. A., Gebara, M. A., Ciarleglio, A., Lavretsky, H., Brown, P. J., Flint, A. J., Farber, N. B., Karp, J. F., Mulsant, B. H., Reynolds, C. F., Roose, S. P., Yang, L., Butters, M. A., Lenze, E. J.
Paywallmeta

Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability

This review (2022) uses data from three randomised-controlled trials (RCTs), eight open-label trials and 30 case series to explore the efficacy, safety and tolerability of using ketamine in the treatment of depression. Ketamine was found to have sustained antidepressant effects when administered intravenously, intranasally, orally and possibly intramuscularly and was found to be well-tolerated.

Published
October 18, 2022
Journal
Lancet Psychiatry
Authors
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Spijker, J., Kamphuis, J., Schoevers, R. A.
Paywallmeta

Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis

This meta-analysis assessed the effects of ketamine administration in healthy participants (n=1,041) on several cognitive domains. Deficits in verbal learning/memory were most prominent, whereas response inhibition was the least affected. Negative effects were dependent on infusion dose and plasma level but unaffected by enantiomer type, route of administration, sex or age.

Published
August 1, 2022
Journal
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Authors
Zhornitsky, S., Pelletier, R., Assaf, R., Potvin, S., Li, C-S., Tourjaman, V.
Paywallindividual

Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder

This open-label study (n=15) assessed the effectiveness of six ketamine infusions (35mg/70kg) over a 12-day period on neurocognitive function in veterans with comorbid PTSD and major depressive disorder (MDD). Significant improvement was observed in working memory following completion of the infusion series while greater improvements in PTSD and MDD symptoms were associated with lower working memory, slower processing speed and faster set-shifting at baseline.

Published
July 1, 2022
Journal
Journal of Affective Disorders
Authors
Albott, C. S., Lim, K. O., Erbes, C., Thuras, P., Wels, J., Tye, S. J., Shiroma, P. R.

Clinical Trials

14 trials
RecruitingPhase II

Ketamine for Veterans With Parkinson’s Disease (KPD)

This double-masked, active placebo-controlled, single-dose randomised trial (n=80) will investigate the effects of intravenous (IV) ketamine versus remimazolam for depression in Veterans with Parkinson’s disease (PD).

Started
July 1, 2024
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06231563
Enrolling by invitationPhase NA

Long Term Follow Up KET-PD

This observational cohort study (n=40), conducted by Yale University, aims to explore the long-term effects of ketamine for treating depression in Parkinson's disease (PD) and assess the impact of Cognitive Behaviour Therapy (CBT) on maintaining the effects of ketamine.

Started
October 18, 2023
Type
observational
Randomized
No
Registry ID
NCT06164756
Active not recruitingPhase II

Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

This open-label trial (n=15) will assess the safety and tolerability of a single sub-anesthetic (0.5 mg/kg) intravenous ketamine treatment in individuals aged 50–90 with mild cognitive impairment and depression (MCI-D).

Started
October 18, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06069843
Unknown statusPhase I

Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson’s Disease

Single-group, open-label Phase I study (n=9 actual) assessing tolerability and efficacy of low-dose IV ketamine infusions for Levodopa-Induced Dyskinesia in Parkinson's disease.

Started
August 25, 2022
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06021756
Unknown statusPhase II/III

Ketamine to Treat Patients With Post-comatose Disorders of Consciousness

This double-blind, placebo-controlled crossover trial (n=30) tests intravenous subanesthetic ketamine (TCI to 0.75 µg/ml) versus saline in patients with disorders of consciousness, with TMS-EEG and multimodal imaging assessments.

Started
May 1, 2022
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT05343507
CompletedPhase II

Ketamine for the Treatment of Depression in Parkinson's Disease

Randomised, double-blind, placebo-controlled parallel trial (n=51 actual) testing repeated IV ketamine infusions (0.5 mg/kg, six 40-minute infusions) for depression in people with Parkinson's disease.

Started
November 23, 2021
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04944017

Explore further

Search all Ketamine papers Search all Neurocognitive Disorders trials Full Ketamine profile Full Neurocognitive Disorders profile